The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
WinklerK., BielackS.S., DellingG.Effects of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer.1990; 66: 1703–1710.
2.
FuchsN., BielackS.S., EplerD.Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol.1998; 9: 893–899.
BacciG., MercuriM., BriccoliA.Osteogenic sarcoma of the extremity with detectable lung metastases at presentation: results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer.1997; 79: 245–254.
5.
HarrisM., GieserP., GoorinA.Treatment of metastatic osteosarcoma at diagnosis: a pediatric oncology group study. J Clin Oncol.1998; 16(11): 3641–3648.
6.
BacciG., BriccoliA., RoccaM.Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experiences at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose methotrexate and ifosfamide. Ann Oncol.2003; 14: 1126–1134.
7.
FerrariS., SmelandS., MercuriM.Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol.2005; 23: 8845–8852.
8.
MeyersP.A., SchwartzC.L., KrailoM.Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol.2005; 23: 2004–2011.
9.
BacciG., PicciP., FerrariS.Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer.1993; 72: 3227–3238.
10.
RhaS.Y., ChungH.C., GongS.J.Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Oncology Rep.1999; 6: 631–637.
11.
BacciG., FerrariS., BertoniF.Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the instituto ortopedico rizzoli according to the instituto ortopedico/osteosarcoma-2 protocol: an updated report. J Clin Oncol.2000; 18(24): 4016–4027.
12.
PatelS.J., LynchJ.W.Jr, JohnsonT.Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol.2002; 25(5): 489–495.
KrisM.G., HeskethP.J., SomerfieldM.R.American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006;24: 2932–2947.
KrisM.G., GrallaR.J., ClarkR.A.Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol.1985; 3: 1379–1384.
19.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
20.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
21.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
22.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85(8): 1099–1101.
23.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
24.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
25.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
26.
KintzelP.E.Anticancer drug-induced kidney disorders. Drug Saf.2001; 24(1): 19–38.
27.
PitmanS.W., FreiE3rdWeekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep.1977; 61: 695–701.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
32.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–405.
33.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
34.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
35.
AronoffG.R., BernsJ.S., BrierM.E.Drug Prescribing in Renal Failure.4th ed. Philadelphia: American College of Physicians; 1999: 74.
36.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
37.
DonelliM.G., ZucchettiM., MunzoneE., D'IncalciM., CrosignaniA.Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer.1998; 34: 33–46.
